Total Funding
49
Total FundingSeries A raised
Growth Score
pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
53897
Vedere Bio is developing gene therapy products to restore functional vision to patients who have suffered vision loss.
- Anna-Maria Demetriades: Chief Medical Officer
- Gina Consylman: Chief Financial OfficerPast Role: Genetix Biotherapeutics Inc., Chief Financial Officer
About the Company
Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to
restore lost vision regardless of a patient’s underlying genetics or their stage of disease.
